ホーム>>Signaling Pathways>> Proteases>> Endogenous Metabolite>>Coproporphyrin I

Coproporphyrin I

カタログ番号GC70366

Coproporphyrin Iは尿と血液中に存在する内因性代謝産物であり、肝疾患とポルフィリン症の研究に用いることができる。

Products are for research use only. Not for human use. We do not sell to patients.

Coproporphyrin I 化学構造

Cas No.: 531-14-6

サイズ 価格 在庫数
1 mg
$144.00
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Coproporphyrin I is an endogenous metabolite present in Urine and Blood that can be used for the research of Liver Disease and Porphyria.

Endogenous metabolites is defined as those that are annotated by Kyoto Encyclopedia of Genes and Genomes as substrates or products of the ~1900 metabolic enzymes encoded in our genome. It is clear in the body of literature that there are documented toxic properties for many of these metabolites[1].

<p >References:
[1]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720.
[2]. Zuijderhoudt FM, et al. On accuracy and precision of a HPLC method for measurement of urine porphyrin concentrations. Clin Chem Lab Med. 2000 Mar;38(3):227-30.
[3]. Hindmarsh JT, et al. Biochemical differentiation of the porphyrias. Clin Biochem. 1999 Nov;32(8):609-19.
[4]. MAGNUS IA, et al. Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet. 1961 Aug 26;2(7200):448-51.

レビュー

Review for Coproporphyrin I

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Coproporphyrin I

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.